1 HOUSE OF REPRESENTATIVES - FLOOR VERSION
2 STATE OF OKLAHOMA
3 1st Session of the 60th Legislature (2025)
4 COMMITTEE SUBSTITUTE
FOR
5 HOUSE BILL NO. 1416 By: West (Josh) of the House
6 and
7 Rosino of the Senate
8
9
10 COMMITTEE SUBSTITUTE
11 An Act relating to non-opioid treatment; defining
terms; authorizing insurers to amend preferred drug
12 lists; allowing for discretion in drug treatment;
prohibiting certain drugs over others for treatment;
13 allowing coverage of drugs once approved by the
United States Food and Drug Administration;
14 authorizing coverage of non-opioid drugs; authorizing
reimbursement to hospitals for non-opioid treatment;
15 providing for codification; and providing an
effective date.
16
17
18 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
19 SECTION 1. NEW LAW A new section of law to be codified
20 in the Oklahoma Statutes as Section 1313.1 of Title 74, unless there
21 is created a duplication in numbering, reads as follows:
22 A. As used in this section:
23 1. "Group insurance plan" means a group insurance plan that
24 covers state employees;
HB1416 HFLR Page 1
BOLD FACE denotes Committee Amendments.

1 2. "Health care prescriber" means an individual authorized by
2 law to prescribe drugs;
3 3. "Insurer" means an insurer that offers a group insurance
4 plan; and
5 4. "Non-opioid treatment" means a drug or biological product
6 that is indicated to produce analgesia without acting on the body's
7 opioid receptors, for which there is no other drug or product that
8 is rated as therapeutically equivalent under the Food and Drug
9 Administration's most recent publication of "Approved Drug Products
10 with Therapeutic Equivalence Evaluations".
11 B. Except as otherwise provided in this section, an insurer,
12 for purposes of offering a group insurance plan, may adopt or amend
13 a state preferred drug list (PDL).
14 C. 1. In establishing and maintaining the PDL, the insurer
15 shall ensure that a non-opioid drug approved by the United States
16 Food and Drug Administration for the treatment or management of pain
17 is not disadvantaged or discouraged with respect to coverage
18 relative to an opioid or narcotic drug for the treatment or
19 management of pain on the PDL.
20 2. Paragraph 1 of this subsection does not prohibit an opioid
21 medication from being preferred over other opioid medications, or a
22 non-opioid medication from being preferred over other non-opioid
23 medications.
24
HB1416 HFLR Page 2
BOLD FACE denotes Committee Amendments.

1 D. This section applies to a non-opioid drug treatment as
2 defined in paragraph 4 of subsection A of this section that has been
3 reviewed and approved for coverage by a group insurance plan or
4 insurer as defined in subsection A of this section. This section
5 also applies to drugs being provided under a contract between the
6 insurer and a pharmacy benefits manager for purposes of a group
7 insurance plan.
8 SECTION 2. This act shall become effective November 1, 2025.
9
10 COMMITTEE REPORT BY: COMMITTEE ON HEALTH AND HUMAN SERVICES
OVERSIGHT, dated 02/26/2025 â€“ DO PASS, As Amended.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
HB1416 HFLR Page 3
BOLD FACE denotes Committee Amendments.

[DELETED:  P B   a R]
[DELETED:  P]
[DELETED:  P]